Immunotherapeutic Oral Formulation for Prostate Cancer

2015 ◽  
pp. 185-194
Author(s):  
Archana Akalkotkar ◽  
Ashwin Parenky ◽  
Martin D'Souza
Keyword(s):  
Prostate Cancer ◽  
Oral Formulation

scholarly journals Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment

2017 ◽  
Vol 23 (14) ◽  
pp. 3781-3793 ◽  
Author(s):  
Roopali Saxena ◽  
Chunhua Yang ◽  
Mukkavilli Rao ◽  
Ravi Chakra Turaga ◽  
Chakravarthy Garlapati ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Oral Formulation ◽  
Preclinical Development ◽  
Prostate Cancer Treatment ◽  
Lipid Precursor

Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16084-e16084
Author(s):  
A. Rodriguez Garzotto ◽  
J. Sepulveda ◽  
A. Cortijo ◽  
L. Garcia ◽  
I. Garcia Rodriguez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Disease Progression ◽  
Objective Response ◽  
Dose Intensity ◽  
Oral Formulation ◽  
Significant Advance ◽  
Weekly Dose ◽  
Weekly Schedule ◽  
Oral Vinorelbine ◽  
Psa Response

e16084 Background: Vinorelbine (VRL) has been shown to be active in hormone-refractory prostate cancer (HRPC). Oral formulation of VRL represents a significant advance in the treatment of advanced cancer. The recommended doses are 60–80 mg/m2(d1–8 q3wks).We evaluated efficacy and toxicity of different VRL schedule administered as a fixed-weekly dose of 60 mg/m2. The purpose of this study was to evaluate the toxicity profile and efficacy of this schedule in terms of PSA response, objective response and clinical benefit (CB) response. Methods: Pts characteristics were: PS 0–2, adequate bone marrow, liver and renal functions. Oral VRL was adminestered at weekly dose of 60 mg/m2 until disease progression/intolerable toxicity. PSA response was defined as a >50% fall in PSA from baseline, confirmed by a second PSA value 4 or > weeks later. Pts with measurable soft tissue disease met traditional guidelines for tumour responses. Progression was defined by objective disease progression or PSA increase of >50% above nadir or >25% above baseline. Pts were monitored clinically and with serial PSA measurements every 1 week. Results: Thirty seven pts with progressive HR metastatic prostate cancer were evaluated. Mean (range) age was 67 years (50–88), median PSA level was 90 ng/ml (1- 4314), and median Gleason score was 7 (6–9). 23 (62%) pts had previous taxane chemotherapy and 14 pts (38%) were chemo-naive. Pts received a mean of 5.5 cycles (1cycle=3wks) (range:1–24). Median follow-up was 12 months. Thirty three of 37 Pts (97%) achieved a decline in serum PSA. CB response was achieved in 15 out of 37 pts(40%). The PSA response was observed in 13 pts (35%). Objective response was not observed and only 6 pts showed SD (16%). The relative dose-intensity was 94%. There were no reported grade 3–4 toxicities. Only 1 treatment discontinuation was observed (esopahgitis g2). Toxicities consisted primarily of g2 anemia (25%) and mild nausea (32%). Conclusions: Oral Vinorelbine administered as a fixed-weekly schedule of 60 mg/m2 is a safe regimen in pts with advanced HRPC. This regimen of oral vinorelbine is an effective and well-tolerated treatment in this setting, despite a major dose-intensity administered. Further studies will be evaluated in chemo-naive and/or elderly population. No significant financial relationships to disclose.

Sigmoidoscopic findings following radiation for prostate cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
T BOLIN ◽  
A KNEEBONE ◽  
T LARSSON
Keyword(s):  
Prostate Cancer

1625: Neuroligin 4 ISOFORM Y: A Novel Marker for Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 538-539
Author(s):  
Joseph F. Pazona ◽  
C. Shad Thaxton ◽  
Neema Navai ◽  
Brian T. Helfand ◽  
Lee C. Zhao ◽  
...  
Keyword(s):  
Prostate Cancer

232: Natural History of Treated Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 77-78
Author(s):  
Christopher R. Porter ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Claudio Jeldres ◽  
Koichi Kodama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Natural History ◽  
Biochemical Recurrence ◽  
History Of

466: Age is an Independent Predictor of Bone Metastasis at Prostate Cancer Diagnosis

2007 ◽  
Vol 177 (4S) ◽  
pp. 156-156
Author(s):  
Andrea Salonia ◽  
Pierre I. Karakiewicz ◽  
Andrea Gallina ◽  
Alberto Briganti ◽  
Tommaso C. Camerata ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Diagnosis ◽  
Independent Predictor ◽  
Prostate Cancer Diagnosis

456: Genetic Polymorphisms in CYP17, CYPJA4, CYP19 and SRD5A2 and Prostate Cancer Risk in African American Men: the Flint Men's Health Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 153-153
Author(s):  
Aruna V. Sarma ◽  
Leslie Lange ◽  
Anna Ray ◽  
Ethan Lange ◽  
Rodney L. Dunn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Risk ◽  
Genetic Polymorphisms ◽  
African American Men ◽  
Prostate Cancer Risk ◽  
Men’S Health ◽  
Health Study ◽  
Men's Health

667: Sonic Hedgehog Signaling Plays a Pivotal Role in the Vicious Cycle between Human Prostate Cancer and Normal/Benign but not Cancer Associated Human Prostate Stromal Cells

2007 ◽  
Vol 177 (4S) ◽  
pp. 224-224
Author(s):  
Katsumi Shigemura ◽  
Wen-Chin Haung ◽  
Fray F. Marshall ◽  
Haiyen E. Zhau ◽  
Leland W.K. Chung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sonic Hedgehog ◽  
Stromal Cells ◽  
Hedgehog Signaling ◽  
Pivotal Role ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Vicious Cycle ◽  
Sonic Hedgehog Signaling

664: CXCL12/CXCR4 Trans-Activation of HER2 in Lipid Rafts of Prostate Cancer Cell Membranes Promotes Bone Metastasis

2007 ◽  
Vol 177 (4S) ◽  
pp. 223-223
Author(s):  
Sreenivasa R. Chinni ◽  
Hamilto Yamamoto ◽  
Zhong Dong ◽  
Aaron Sabbota ◽  
Sanaa Nabha ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Lipid Rafts ◽  
Cancer Cell ◽  
Cell Membranes ◽  
Prostate Cancer Cell

660: Altered MUC-1 (EMA) Protein Expression Studied by Tissue Microarray Predicts Biochemical Failure after Radical Prostatectomy in Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 222-222
Author(s):  
Mireia Musquera ◽  
Maria J. Ribal ◽  
Yolanda Arce ◽  
Humberto Villavicencio ◽  
Fernando Algaba ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Protein Expression ◽  
Tissue Microarray ◽  
Biochemical Failure
Sign in / Sign up

Export Citation Format

Share Document